| Literature DB >> 15297045 |
E Fernandez-Cruz1, S Moreno, J Navarro, B Clotet, E Bouza, J Carbone, J M Peña, J Pérez Molina, D Podzamczer, R Rubio, I Ocaña, F Pulido, P Viciana, J A Maradona, R Blazquez, C Barros, C Quereda, C Rodriguez-Sainz, J Gil, M L Abad, L Díaz, C Cantó, M A Muñoz, E Ferrer, A Jou, G Sirera, M Díaz, F Lopez, J M Gatell, J Gonzalez-Lahoz.
Abstract
To determine whether the addition of an inactivated-gp120-depleted HIV-1 Immunogen to antiretrovirals (ARTs) conferred a beneficial effect on delaying time to virologic failure relative to that obtained by ARTs alone, a phase II clinical trial was performed in 243 asymptomatic, ART naïve, HIV-1 seropositive adults. The Cox model showed that HIV-1 Immunogen treatment was associated with a 34% decrease in the risk of virologic failure (P = 0.056). When the analysis incorporated baseline HIV-RNA stratification the risk of virologic failure in the HIV-1 Immunogen Arm was significantly reduced a 37% compared to the IFA placebo Arm (P = 0.034). The data suggest that therapeutic immunization plus ARTs could influence virologic control.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15297045 DOI： 10.1016/j.vaccine.2004.03.040
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641